Byung-kun W. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea.

Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea.

Journal: Drugs - real world outcomes

Published: June 21, 2026

Current landscape of migraine care with expert consensus from East Asia.

Current landscape of migraine care with expert consensus from East Asia.

Journal: The journal of headache and pain

Published: March 23, 2026

Use of CGRP Monoclonal Antibodies in Japan, South Korea, and Taiwan: A Narrative Review.

Use of CGRP Monoclonal Antibodies in Japan, South Korea, and Taiwan: A Narrative Review.

Journal: Current pain and headache reports

Published: January 26, 2026

Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study.

Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study.

Journal: The journal of headache and pain

Published: January 06, 2026

Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific.

Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia Pacific.

Journal: Frontiers in neurology

Published: December 18, 2025

Characterizing migraine burden and treatment response using nationwide smartphone app-based data in Korea.

Characterizing migraine burden and treatment response using nationwide smartphone app-based data in Korea.

Journal: The journal of headache and pain

Published: November 10, 2025

Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.

Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.

Journal: Cephalalgia : an international journal of headache

Published: October 15, 2025

Subtype shift, relapse rate and risk factors of frequent relapse in cluster headache: A multicenter, prospective, longitudinal observation.

Subtype shift, relapse rate and risk factors of frequent relapse in cluster headache: A multicenter, prospective, longitudinal observation.

Journal: Cephalalgia : an international journal of headache

Published: September 13, 2025

Psoas Syndrome Following a Generalized Seizure.

Psoas Syndrome Following a Generalized Seizure.

Journal: Journal of epilepsy research

Published: August 30, 2025

Injection-Based Therapies for Migraine in Older Adults: A Narrative Review of OnabotulinumtoxinA, Greater Occipital Nerve Block, and Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies.

Injection-Based Therapies for Migraine in Older Adults: A Narrative Review of OnabotulinumtoxinA, Greater Occipital Nerve Block, and Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies.

Journal: Journal of Korean medical science

Published: July 17, 2025

Re: Comments on "Pain Lateralization in Cluster Headache and Associated Clinical Factors".

Re: Comments on "Pain Lateralization in Cluster Headache and Associated Clinical Factors".

Journal: Journal of clinical neurology (Seoul, Korea)

Published: June 17, 2025

Hallmarks of primary headache: part 2- Tension-type headache.

Hallmarks of primary headache: part 2- Tension-type headache.

Journal: The journal of headache and pain

Published: May 22, 2025

Showing 1-12 of 84

Last Updated: 09/26/2026